公开(公告)号：US11998537B2

公开(公告)日：2024-06-04

申请号：US17287735

申请日：2019-10-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Brian K. Whiteley ,  John L. Gilmore

IPC: A61K31/4545 ,  A61K47/54 ,  A61K47/55

CPC classification number: A61K31/4545 ,  A61K47/54 ,  A61K47/55

Abstract: Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G1, G2, L, R1a, R1b, R4, R5, n, m, x, and y are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US11912703B2

公开(公告)日：2024-02-27

申请号：US17854089

申请日：2022-06-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Sreekantha Ratna Kumar ,  Durga Buchi Raju Barre ,  Srinivasan Kunchithapatham Duraisamy

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I)




N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20220348576A1

公开(公告)日：2022-11-03

申请号：US17854089

申请日：2022-06-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Sreekantha Ratna Kumar ,  Durga Buchi Raju Barre ,  Srinivasan Kunchithapatham Duraisamy

IPC: C07D471/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20220340555A1

公开(公告)日：2022-10-27

申请号：US17245595

申请日：2021-04-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  Trevor C. Sherwood ,  Brian K. Whiteley ,  John L. Gilmore ,  Sreekantha Ratna Kumar ,  Laxman Pasunoori ,  Pitani Veera Venkata Srinivas ,  Srinivasan Kunchithapatham Duraisamy ,  Subramanya Hegde ,  Rushith Kumar Anumula

IPC: C07D471/04 ,  A61P19/02 ,  A61P25/00 ,  C07D495/10 ,  C07D519/00 ,  C07D491/107 ,  A61P37/00 ,  C07D471/08 ,  A61P29/00

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20210253593A1

公开(公告)日：2021-08-19

申请号：US16763670

申请日：2018-11-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  Trevor C. Sherwood ,  John L. Gilmore ,  Tasir Shamsul Haque ,  Brian K. Whiteley ,  David R. Tortolani ,  Shoshana L. Posy ,  John E. Macor ,  Louis J. Lombardo ,  Ramesh Kumar Sistla ,  Anupama Kandhi Ramachandra Reddy ,  Subramanya Hegde ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar

IPC: C07D498/04 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D417/14 ,  C07D405/14 ,  C07D513/04 ,  C07D401/14 ,  C07D495/04

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US11046646B2

公开(公告)日：2021-06-29

申请号：US16636670

申请日：2018-08-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Ling Li ,  John L. Gilmore

IPC: C07D207/04 ,  A61K31/40 ,  A61P1/00 ,  C07D207/16

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH2— or —C(O)—; R1 is —OH or —OP(O)(OH)2; L is a bond, —CH2—, or —C(O)—; R2 is n-C6-8 alkyl; each R3 is independently selected from Cl and —CH3; and n is zero, 1, or 2; provided that if X is —CH2—, then L is —CH2— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20210085651A1

公开(公告)日：2021-03-25

申请号：US17113495

申请日：2020-12-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Tasir Shamsul Haque ,  Louis J. Lombardo ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar ,  Trevor C. Sherwood ,  Shoshana L. Posy ,  Ramesh Kumar Sistla ,  Subramanya Hegde ,  Anupama Kandhi Ramachandra Reddy

IPC: A61K31/4196 ,  C07D249/00 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20200339581A1

公开(公告)日：2020-10-29

申请号：US16955166

申请日：2018-12-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  David R. Tortolani ,  Tasir Shamsul Haque ,  Shoshana L. Posy

IPC: C07D471/10 ,  C07D401/14 ,  C07D403/04 ,  C07D471/04 ,  C07D209/12 ,  C07D413/12 ,  C07D409/14

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein G, R1, R5, R7, R8, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20200331920A1

公开(公告)日：2020-10-22

申请号：US16954543

申请日：2018-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  Trevor C. Sherwood ,  Tasir Shamsul Haque ,  Shoshana L. Posy ,  Sreekantha Ratna Kumar ,  Laxman Pasunoori ,  Subramanya Hegde ,  Rushith Kumar Anumula

IPC: C07D487/04 ,  C07D403/10 ,  C07D491/08 ,  C07D209/42 ,  C07D405/14 ,  C07D401/12 ,  C07D417/14 ,  C07D401/14 ,  C07D401/10 ,  C07D417/12 ,  C07D403/14

Abstract: N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmunediseases.

公开(公告)号：US20200281952A1

公开(公告)日：2020-09-10

申请号：US16879824

申请日：2020-05-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  T.G. Murali Dhar ,  Hai-Yun Xiao ,  John L. Gilmore ,  Michael G. Yang ,  Zili Xiao ,  David Marcoux

IPC: A61K31/695 ,  C07F7/08 ,  A61K31/135 ,  C07D215/14 ,  C07D241/04 ,  C07C323/29 ,  C07C251/38 ,  C07C251/42 ,  C07C251/44 ,  C07D209/46 ,  C07D213/38 ,  C07C275/26 ,  C07C217/74 ,  C07C323/25 ,  C07C235/46 ,  C07F9/54 ,  C07F9/572 ,  C07F9/09 ,  C07C215/42 ,  C07C217/52 ,  C07C217/58 ,  C07C219/24 ,  C07C233/41 ,  C07C233/65 ,  C07C251/50 ,  C07C251/52 ,  C07C251/54 ,  C07C271/34 ,  C07C317/28 ,  C07C317/32 ,  C07C321/16 ,  C07C321/22 ,  C07C321/28 ,  C07D213/32 ,  C07D213/69 ,  C07D213/70 ,  C07D215/12 ,  C07D217/24 ,  C07D231/12 ,  C07D231/20 ,  C07D239/26 ,  C07D241/12 ,  C07D277/24 ,  C07D305/08 ,  C07D309/06 ,  C07D309/12 ,  C07D311/58 ,  C07D311/76 ,  C07D319/20 ,  C07D333/16 ,  C07F9/117 ,  C07F9/62 ,  C07F9/6503 ,  C07F9/6509 ,  C07F9/655 ,  C07F9/6553 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K31/166 ,  A61K31/17 ,  A61K31/222 ,  A61K31/24 ,  A61K31/27 ,  A61K31/337 ,  A61K31/351 ,  A61K31/352 ,  A61K31/381 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/661

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.